Synapse - Works

Results (116624)

Primary hepatic lymphoma: Role of low-dose radiotherapy at a single institution with genetic characterization and paired literature review

Meeting Abstract

Ma, J.; Daou, R.; Eid, J. B.; Lee, J.; Fregonese, B.; El-Khoury, J.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K. R.; Lebow, E. S.; more...
Blood (2022)

Fulltext@MSK | Save

Trial in progress: A phase 1b/2 study of GB5121, a brain-penetrant, potent, highly selective, and irreversible BTK inhibitor for relapsed/refractory primary/secondary CNS lymphoma and primary vitreoretinal lymphoma

Meeting Abstract

Soussain, C.; Issa, S.; Lewis, K. L.; Grommes, C.; Fox, J.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; more...
Blood (2022)

Fulltext@MSK | Save

Vitalize trial: A phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of the novel immunotherapeutic, maveropepimut-S, and pembrolizumab with and without intermittent low-dose cyclophosphamide, in subjects with relapsed/refractory diffuse large B-cell lymphoma

Meeting Abstract

Matasar, M. J.; Lee, E.; Leitch, S.; Solh, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
Blood (2022)

Fulltext@MSK | Save

Autologous stem cell transplantation (ASCT) improves survival outcome in primary central nervous system lymphoma (PCNSL) in a minority rich, underserved inner city population in the real-world setting

Meeting Abstract

Narvel, H.; Vegivinti, C. T. R.; Vikash, S.; Bazarbachi, A. H.; Wang, S.; Reef, D. K.; Hammami, M. B.; Narvel, A.; Mehta, A. K.; Mantzaris, I.; more...
Blood (2022)

Fulltext@MSK | Save

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Meeting Abstract

Parisi, R.; Cowen, E. A.; Gu, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
Blood (2022)

Fulltext@MSK | Save

Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: A phase Ib/II trial

Meeting Abstract

Daver, N.; Wei, A. H.; Stein, E.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
Blood (2022)

Fulltext@MSK | Save

A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations

Meeting Abstract

Ball, B. J.; Stein, E.; Robbins, M.; Zhang, J.; Levine, R. L.; Synold, T.; Stein, A. S.; Marcucci, G.; Liu, Y.; Danilov, A. V.
Blood (2022)

Fulltext@MSK | Save

Dissecting the knowns for the unknowns: Refining the classification of genomic variations in hematological diseases by the ClinGen Hematological Cancer Taskforce (HCT)

Meeting Abstract

Li, Y.; Saliba, J.; Kopp, N.; Mani, C.; Williams, H. E.; Zhang, W.; Zhao, J.; Krysiak, K.; Danos, A.; Shao, X.; more...
Blood (2022)

Fulltext@MSK | Save

Association of linguistic barriers and survival in allogeneic hematopoietic cell transplantation

Meeting Abstract

Walji, M.; Lee, J.; Devlin, S. M.; Gany, F.; Perales, M. A.; Giralt, S. A.; Cho, C.
Blood (2022)

Fulltext@MSK | Save

Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative

Meeting Abstract

Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; more...
Blood (2022)

Fulltext@MSK | Save